The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1336
Dutasteride (Avodart) for Prevention of Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart – GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic hyperplasia, reduced the risk of prostate cancer over a 4-year period.1

5α-REDUCTASE INHIBITORS — Dutasteride is one of two 5α-reductase inhibitors marketed in the US for treatment of benign prostatic hyperplasia.2 The other is finasteride (Proscar, and others). Both finasteride and dutasteride inhibit conversion of testosterone to dihydrotestosterone in the prostate, reduce the size of the prostate, improve urinary flow, and suppress prostate-specific antigen (PSA) levels. Both can cause sexual adverse effects. The double-blind, placebo-controlled, Prostate Cancer Prevention Trial (PCPT) found that men who took finasteride for 7 years had a lower incidence of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dutasteride (Avodart) for Prevention of Prostate Cancer
Article code: 1336a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian